Will Obama follow Clinton on biogenerics?
Executive Summary
After adding "presumptive nominee" to his resumé, Sen. Barack Obama may be poised to add more planks to his health care platform as well. While the Illinois Democrat supports the concept of follow-on biologics, he has not signed on to legislation that would create a pathway for approval - in part, perhaps, to avoid assisting his main rival Sen. Hillary Clinton, D-N.Y., who is one of the lead sponsors. But with the primary campaign over, there is some indication that follow-ons may now enter Obama's messaging, which would presumably also lead him to flesh out his policy position on the issue. On June 4, the Alliance of Minority Medical Associations and the Benenson Strategy Group - which bills itself as the "polling firm for Barack Obama's campaign" - released survey data showing "overwhelming" public support for follow-on biologics. Regardless of what rhetorical positioning is adopted on the campaign trail, however, it seems unlikely there will be any legislative movement on follow-on biologics this year
You may also be interested in...
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market
Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.